Attentional processes and decision making in social interactions - Investigation of alterations in individuals with Borderline Personality Disorder and the relationship to different hormones

Not Applicable

• Conditions: Healthy Volunteers; F60.31

• Registration Number: DRKS00009815
• Lead Sponsor: Klinik für Allgemeine Psychiatrie Universitätsklinikum Heidelberg

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2016-01-11
• Study Completion: 2018-12-31
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: Female
• Target Recruitment: 112

Inclusion Criteria

General inclusion criteria: age 18-50 years, readiness for participation. Additional inclusion criterion for patients with Borderline Personality Disorder: Borderline Personality Disorder assessed with the International Personality Disorder Examination.

Exclusion Criteria

General exclusion criteria: actual pregnancy, lifetime diagnosis of any psychotic or bipolar disorders, substance dependence during the past year, a history of brain damage, severe internistic or neurological disease, claustrophobia. Additional exclusion criterion for healthy controls: more than one DSM-IV criterion for Borderline Personality Disorder fulfilled.

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Behavioral Data: Performance and reaction time; EEG: P1, N170, P300 for emotional faces after a single oxytocin vs. placebo administration in female BPD patients vs. healthy controls

Secondary Outcome Measures

Name	Time	Method
Exploratory correlations between behavioral and EEG data (see Primary outcome) and dimensional trait questionnaires (anger, German version of the State-Trait Anger Inventory; Spielberger, 1991; anxiety, German Version of the State-Trait Anxiety Inventory; depression, Beck Depression Inventory; aggressiveness, Life History of Aggression Inventory; Coccaro et al. 1997; Overt Aggression Sale Modified for Outpatients; OAS-M, Coccaro et al., 1991) after single oxytocin vs. Placebo Administration in female BPD patients vs. healthy volunteers.